Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States.
Anti-HIV Agents
/ therapeutic use
Antiretroviral Therapy, Highly Active
Atherosclerosis
/ prevention & control
Cardiovascular Diseases
/ economics
Cost-Benefit Analysis
/ statistics & numerical data
HIV Infections
/ complications
Health Care Costs
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ economics
Primary Prevention
/ economics
Quality-Adjusted Life Years
United States
/ epidemiology
HIV
United States
antiretroviral therapy
cardiovascular disease
cost-effectiveness
statin
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
revised:
04
02
2021
received:
04
09
2020
accepted:
23
02
2021
entrez:
22
3
2021
pubmed:
23
3
2021
medline:
18
9
2021
Statut:
ppublish
Résumé
Expanding statin use may help to alleviate the excess burden of atherosclerotic cardiovascular disease in people living with HIV (PLHIV). Pravastatin and pitavastatin are preferred agents due to their lack of substantial interaction with antiretroviral therapy. We aimed to evaluate the cost-effectiveness of pravastatin and pitavastatin for the primary prevention of atherosclerotic cardiovascular disease among PLHIV in the United States. We developed a microsimulation model that randomly selected (with replacement) individuals from the Data-collection on Adverse Effects of Anti-HIV Drugs study with follow-up between 2013 and 2016. Our study population was PLHIV aged 40 to 75 years, stable on antiretroviral therapy, and not currently using lipid-lowering therapy. Direct medical costs and quality-adjusted life-years (QALYs) were assigned in annual cycles and discounted at 3% per year. We assumed a willingness-to-pay threshold of $100,000/QALY gained. The interventions assessed were as follows: (1) treating no one with statins; (2) treating everyone with generic pravastatin 40 mg/day (drug cost $236/year) and (3) treating everyone with branded pitavastatin 4 mg/day (drug cost $2,828/year). The model simulated each individual's probability of experiencing atherosclerotic cardiovascular disease over 20 years. Persons receiving pravastatin accrued 0.024 additional QALYs compared with those not receiving a statin, at an incremental cost of $1338, giving an incremental cost-effectiveness ratio of $56,000/QALY gained. Individuals receiving pitavastatin accumulated 0.013 additional QALYs compared with those using pravastatin, at an additional cost of $18,251, giving an incremental cost-effectiveness ratio of $1,444,000/QALY gained. These findings were most sensitive to the pill burden associated with daily statin administration, statin costs, statin efficacy and baseline atherosclerotic cardiovascular disease risk. In probabilistic sensitivity analysis, no statin was optimal in 5.2% of simulations, pravastatin was optimal in 94.8% of simulations and pitavastatin was never optimal. Pravastatin was projected to be cost-effective compared with no statin. With substantial price reduction, pitavastatin may be cost-effective compared with pravastatin. These findings bode well for the expanded use of statins among PLHIV in the United States. To gain greater confidence in our conclusions it is important to generate strong, HIV-specific estimates on the efficacy of statins and the quality-of-life burden associated with taking an additional daily pill.
Sections du résumé
BACKGROUND
Expanding statin use may help to alleviate the excess burden of atherosclerotic cardiovascular disease in people living with HIV (PLHIV). Pravastatin and pitavastatin are preferred agents due to their lack of substantial interaction with antiretroviral therapy. We aimed to evaluate the cost-effectiveness of pravastatin and pitavastatin for the primary prevention of atherosclerotic cardiovascular disease among PLHIV in the United States.
METHODS
We developed a microsimulation model that randomly selected (with replacement) individuals from the Data-collection on Adverse Effects of Anti-HIV Drugs study with follow-up between 2013 and 2016. Our study population was PLHIV aged 40 to 75 years, stable on antiretroviral therapy, and not currently using lipid-lowering therapy. Direct medical costs and quality-adjusted life-years (QALYs) were assigned in annual cycles and discounted at 3% per year. We assumed a willingness-to-pay threshold of $100,000/QALY gained. The interventions assessed were as follows: (1) treating no one with statins; (2) treating everyone with generic pravastatin 40 mg/day (drug cost $236/year) and (3) treating everyone with branded pitavastatin 4 mg/day (drug cost $2,828/year). The model simulated each individual's probability of experiencing atherosclerotic cardiovascular disease over 20 years.
RESULTS
Persons receiving pravastatin accrued 0.024 additional QALYs compared with those not receiving a statin, at an incremental cost of $1338, giving an incremental cost-effectiveness ratio of $56,000/QALY gained. Individuals receiving pitavastatin accumulated 0.013 additional QALYs compared with those using pravastatin, at an additional cost of $18,251, giving an incremental cost-effectiveness ratio of $1,444,000/QALY gained. These findings were most sensitive to the pill burden associated with daily statin administration, statin costs, statin efficacy and baseline atherosclerotic cardiovascular disease risk. In probabilistic sensitivity analysis, no statin was optimal in 5.2% of simulations, pravastatin was optimal in 94.8% of simulations and pitavastatin was never optimal.
CONCLUSIONS
Pravastatin was projected to be cost-effective compared with no statin. With substantial price reduction, pitavastatin may be cost-effective compared with pravastatin. These findings bode well for the expanded use of statins among PLHIV in the United States. To gain greater confidence in our conclusions it is important to generate strong, HIV-specific estimates on the efficacy of statins and the quality-of-life burden associated with taking an additional daily pill.
Identifiants
pubmed: 33749164
doi: 10.1002/jia2.25690
pmc: PMC7982504
doi:
Substances chimiques
Anti-HIV Agents
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25690Subventions
Organisme : NIAID NIH HHS
ID : U01 AI046362
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069907
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI042170
Pays : United States
Informations de copyright
© 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
N Engl J Med. 2014 Aug 28;371(9):796-7
pubmed: 25162885
JAMA. 2015 Jul 14;314(2):142-50
pubmed: 26172894
Med Care. 2006 Aug;44(8 Suppl 2):S13-24
pubmed: 16849964
JAMA. 2016 Sep 13;316(10):1093-103
pubmed: 27623463
J Am Coll Cardiol. 2019 Jun 25;73(24):e285-e350
pubmed: 30423393
J Int AIDS Soc. 2019 Aug;22(8):e25382
pubmed: 31441221
Eur J Prev Cardiol. 2016 Jan;23(2):214-23
pubmed: 25882821
Clin Infect Dis. 2016 Dec 1;63(11):1508-1516
pubmed: 27613562
J Infect Dis. 2016 Oct 1;214 Suppl 2:S83-92
pubmed: 27625435
J Am Heart Assoc. 2018 Dec 18;7(24):e010345
pubmed: 30526249
Clin Infect Dis. 2016 Aug 1;63(3):407-13
pubmed: 27143663
Can J Cardiol. 2010 Aug-Sep;26(7):e229-35
pubmed: 20847969
JAMA Intern Med. 2013 Apr 22;173(8):614-22
pubmed: 23459863
J Int AIDS Soc. 2020 Jun;23 Suppl 1:e25494
pubmed: 32562359
JAMA. 2002 Jul 24-31;288(4):455-61
pubmed: 12132975
Circulation. 2018 Jul 17;138(3):255-265
pubmed: 29535090
Lancet HIV. 2017 Jul;4(7):e284-e294
pubmed: 28416195
AIDS. 2017 Mar 27;31(6):797-806
pubmed: 28252528
J Acquir Immune Defic Syndr. 2017 Aug 15;75(5):568-576
pubmed: 28520615
Lancet. 2012 Aug 11;380(9841):581-90
pubmed: 22607822
Int J Epidemiol. 2007 Apr;36(2):294-301
pubmed: 17213214
Neurology. 2015 May 12;84(19):1933-40
pubmed: 25862803
Circulation. 2018 Sep 11;138(11):1100-1112
pubmed: 29967196
AIDS. 2013 Mar 27;27(6):973-979
pubmed: 23698063
Ann Intern Med. 2018 Oct 16;169(8):543-553
pubmed: 30304368
J Am Heart Assoc. 2016 Mar 24;4(3):e003411
pubmed: 27013540
JAMA Cardiol. 2017 Feb 1;2(2):155-162
pubmed: 28002550
Top Antivir Med. 2015 Oct-Nov;23(4):146-9
pubmed: 26713505
HIV Med. 2006 May;7(4):218-30
pubmed: 16630034
J Clin Transl Endocrinol. 2017 Feb 22;8:6-14
pubmed: 29067253
Ann Intern Med. 2018 Jul 3;169(1):20-29
pubmed: 29868850
Circulation. 2017 Sep 19;136(12):1087-1098
pubmed: 28687710
Circulation. 2014 Jun 17;129(24):2539-2546
pubmed: 24744274
Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501
pubmed: 20543702
J Am Heart Assoc. 2019 Jan 8;8(1):e010376
pubmed: 30616455
Int J Epidemiol. 2008 Oct;37(5):948-55
pubmed: 18263650